A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients
A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients
复制标题
DOI：
10.1111/cas.14368
复制
发表时间：
2020-03-25
期刊：
影响因子：
5.7
通讯作者：
Yoshino, Ichiro
中科院分区：
文献类型：
--
作者：
Sekine, Ikuo;Shintani, Yasushi;Yoshino, Ichiro
本研究提供了日本非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）药物治疗患者的基准统计数据。从2012年病理诊断为肺癌并接受非手术治疗的患者中获得人口统计学背景、治疗和预后。分析描述性统计及其与生存率的关系。在日本的314家机构中，共登记了12320例患者。中位年龄为70岁，73%的患者为男性。I、II、III和IV期疾病的数量（%）分别为468（3.8%）、421（3.4%）、3260（26.5%）和8171（66.3%）。NSCLC和SCLC分别占9872例（80.1%）和2353例（19.1%）患者。分别有2572（20.9%）、7790（63.2%）和1952（15.8%）例患者接受了基于胸部放疗的治疗、化疗和姑息治疗。临床TNM分期是影响预后的重要因素之一，IA、IB、IIA、IIB、IIIA、IIIB和IV期的3年生存率分别为62.9%、47.3%、40.0%、27.8%、37.5%、26.5%和18.2%。在6158例接受化疗的NSCLC患者中，在临床病程的某个时间点接受表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的患者的3年生存率为33.4%，而未接受EGFR-TKI治疗的患者的3年生存率为17.4%。SCLC的3年生存率仅为15.9%。总之，大约三分之二的患者在初次诊断时被诊断为IV期。EGFR-TKI的使用显著改善了NSCLC患者的生存率。
This study provides the benchmark statistics on medically treated patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) in Japan. Demographic background, treatment, and prognosis were obtained from patients with lung cancer pathologically diagnosed in 2012, who received nonsurgical treatment. Descriptive statistics and their associations with survival were analyzed. In total, 12 320 patients were registered from 314 institutions in Japan. The median age was 70 years, and 73% of the patients were male. The number (%) of stages I, II, III, and IV diseases were 468 (3.8%), 421 (3.4%), 3260 (26.5%), and 8171 (66.3%), respectively. NSCLC and SCLC accounted for 9872 (80.1%) and 2353 (19.1%) patients, respectively. Thoracic radiotherapy-based therapy, chemotherapy, and palliative care alone were administered to 2572 (20.9%), 7790 (63.2%), and 1952 (15.8%) patients, respectively. Clinical TNM stage was one of the strongest prognostic factors with the 3-year survival rates of 62.9%, 47.3%, 40.0%, 27.8%, 37.5%, 26.5%, and 18.2% for stages IA, IB, IIA, IIB, IIIA, IIIB, and IV, respectively. Among 6158 patients with NSCLC treated with chemotherapy, the 3-year survival rate was 33.4% in patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) at some point in their clinical course, whereas it was 17.4% in patients who did not. The 3-year survival rate of SCLC was only 15.9%. In conclusion, approximately two-thirds of the patients were diagnosed as stage IV at the initial diagnosis. Use of EGFR-TKIs significantly improved the survival of patients with NSCLC.